Pilot test of whether cannabis extract helps breathlessness in COPD patients
In a tiny pilot study, sublingual cannabis extract did not change standard breathlessness scores but COPD patients described the sensation of "air hunger" less often.
Quick Facts
What This Study Found
Nine subjects (five healthy, four with COPD) received sublingual cannabis extract or placebo in a crossover design. Standard breathlessness measurements using visual analogue scales showed no differences between drug and placebo in either group.
However, when COPD patients were asked to describe their breathlessness using specific descriptors, those who received the cannabis extract chose "air hunger" less frequently compared to placebo. This suggested the drug might change the qualitative experience of breathlessness without altering its perceived intensity.
The study found no respiratory depression with cannabis extract, supporting the hypothesis that cannabinoids could ease breathlessness sensation without suppressing breathing.
Key Numbers
9 total subjects (5 normal, 4 COPD). Maximum dose: 10.8 mg THC and 10 mg CBD sublingual. Measurements taken at baseline and 2 hours post-administration.
How They Did This
Double-blind, randomized, placebo-controlled crossover study with two test days. Five normal subjects and four COPD subjects received sublingual cannabis extract (up to 10.8 mg THC and 10 mg CBD) or placebo. Breathlessness was induced using fixed carbon dioxide loads.
Why This Research Matters
Breathlessness in COPD is difficult to treat. If cannabinoids can change the subjective quality of breathlessness without suppressing respiratory drive, they could fill a treatment gap where opioids carry respiratory depression risk.
The Bigger Picture
This pilot suggested that standard breathlessness rating scales might miss drug effects that breathlessness descriptors can detect. The finding has implications for how future breathlessness studies are designed, not just for cannabinoid research.
What This Study Doesn't Tell Us
Extremely small sample size (only 4 COPD patients). Single-dose design. The carbon dioxide challenge may not adequately replicate real-world breathlessness experiences. The study was underpowered to detect meaningful differences.
Questions This Raises
- ?Would repeated dosing show stronger effects?
- ?Can breathlessness descriptors be validated as primary outcomes in larger trials?
- ?What cannabinoid receptor mechanisms underlie changes in breathlessness perception?
Trust & Context
- Key Stat:
- 9 subjects total in this pilot study
- Evidence Grade:
- Pilot RCT with only 9 subjects total. Too small to draw firm conclusions but useful for generating hypotheses and testing safety.
- Study Age:
- Published in 2011. Larger trials on cannabinoids for COPD breathlessness have not materialized in the years since.
- Original Title:
- Cannabinoid effects on ventilation and breathlessness: a pilot study of efficacy and safety.
- Published In:
- Chronic respiratory disease, 8(2), 109-18 (2011)
- Authors:
- Pickering, Elspeth E, Semple, Stephen J, Nazir, Muhummad S, Murphy, Kevin, Snow, Thomas M, Cummin, Andrew R, Moosavi, Shakeeb H, Guz, Abraham, Holdcroft, Anita
- Database ID:
- RTHC-00511
Evidence Hierarchy
Participants are randomly assigned to treatment or placebo groups to test cause and effect.
What do these levels mean? →Frequently Asked Questions
Did the cannabis extract help people breathe easier?
Standard breathlessness scores showed no improvement. But COPD patients described the unpleasant "air hunger" sensation less often after the cannabis extract, suggesting it may change how breathlessness feels rather than how severe it is.
Did cannabis suppress breathing?
No. Ventilatory parameters were not affected, meaning the cannabis extract did not cause respiratory depression in this small group.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
- how-to-tell-if-weed-is-moldy
Cite This Study
https://rethinkthc.com/research/RTHC-00511APA
Pickering, Elspeth E; Semple, Stephen J; Nazir, Muhummad S; Murphy, Kevin; Snow, Thomas M; Cummin, Andrew R; Moosavi, Shakeeb H; Guz, Abraham; Holdcroft, Anita. (2011). Cannabinoid effects on ventilation and breathlessness: a pilot study of efficacy and safety.. Chronic respiratory disease, 8(2), 109-18. https://doi.org/10.1177/1479972310391283
MLA
Pickering, Elspeth E, et al. "Cannabinoid effects on ventilation and breathlessness: a pilot study of efficacy and safety.." Chronic respiratory disease, 2011. https://doi.org/10.1177/1479972310391283
RethinkTHC
RethinkTHC Research Database. "Cannabinoid effects on ventilation and breathlessness: a pil..." RTHC-00511. Retrieved from https://rethinkthc.com/research/pickering-2011-cannabinoid-effects-on-ventilation
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.